Intravenous / Subcutaneous · GLP-1 agonist
Exenatide
387 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
387
Ongoing
21
Recruiting
12
Completed
280
Sites
3,307
Countries
60
Endpoints
3,043
Composite endpoints
141
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
5
Phase 1
48
Phase 1/2
14
Phase 2
52
Phase 2/3
9
Phase 3
84
Phase 4
89
Not applicable
86
Trials by status
Not yet recruiting
1
By invitation
1
Recruiting
12
Active, not recruiting
7
Completed
280
Terminated
24
Withdrawn
12
Unknown
50
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
877
Safety / tolerability / PK
544
Cardiometabolic biomarkers
447
Weight & body composition
289
Other clinical outcomes
288
Other (unclassified)
268
Patient-reported / QoL
129
Cardiovascular outcomes
89
Renal / kidney
57
MASH / liver
30
Heart failure
25
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
179
Body weight, absolute change (kg)Weight
127
Fasting glucose, changeGlycemic
99
Postprandial glucoseGlycemic
97
Documented hypoglycemiaSafety/PK
88
HbA1c <7.0% achievementGlycemic
69
Treatment-emergent AEs (any)Safety/PK
67
Triglycerides, changeBiomarker
48
BMI, changeWeight
42
HOMA-IR (insulin sensitivity)Glycemic
40
Total cholesterol, changeBiomarker
39
HbA1c <6.5% achievementGlycemic
36
AUC₀-∞Safety/PK
35
HDL-C, changeBiomarker
34
Systolic BP, changeBiomarker
32
Plasma concentration (steady state)Safety/PK
28
Heart rate, changeBiomarker
26
Waist circumference, changeWeight
23
LDL-C, changeBiomarker
22
CmaxSafety/PK
21
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
387 of 387
Showing 1-25 of 387 trials